News & Updates
Filter by Specialty:
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022
Does reducing salt intake impact CV outcomes?
An intervention aimed at reducing sodium intake in patients with heart failure (HF) does not reduce the risk of emergency department (ED) presentation or hospitalization for cardiovascular (CV) causes or all-cause death, according to results of the SODIUM-HF* trial. However, patients did experience improvements in quality of life (QoL) and New York Heart Association (NYHA) class.
Does reducing salt intake impact CV outcomes?
21 Apr 2022
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
